Team Metabolic Health

Danish biotechnology company Zealand Pharma (ZELA.CO), said on Thursday it expected to initiate a so-called Phase 2b trial with its obesity treatment candidate petrelintide in the fourth quarter of 2024.

“We look forward to initiating a large, comprehensive Phase 2b trial very soon and are now exploring collaboration opportunities with potential partners,” Zealand Pharma CEO Adam Steensberg said in a statement.

The company said it expected to initiate the trial with petrelintide in people with overweight or obesity without type 2 diabetes in the fourth quarter and to complete enrolment of patients in the first half of 2025.

It also said it also expected to initiate a Phase 2b trial in the first half of 2025 for patients with overweight or obesity and type 2 diabetes.

Credit: Reuters